Vaxira (Racotumomab) for U.S. Lung Cancer Patients: Complete Guide
By the SMC Salud Medical Editorial Team
What Is Vaxira (Racotumomab)?
Vaxira, also known by its generic name racotumomab, is a therapeutic cancer vaccine developed by Cuba's Center of Molecular Immunology (CIM) for the treatment of advanced non-small cell lung cancer (NSCLC). Like CIMAvax-EGF, it is used as maintenance therapy following completion of first-line treatment (chemotherapy, radiation, surgery).
Vaxira works by a unique mechanism: it induces an immune response against NeuGcGM3, a ganglioside (a type of lipid molecule) that is abundantly expressed on the surface of lung tumor cells but is largely absent from normal human tissues. By targeting this tumor-specific antigen, Vaxira stimulates the immune system to attack cancer cells while sparing healthy cells — a targeted approach that may result in fewer side effects than conventional treatments.
For U.S. lung cancer patients, Vaxira represents another Cuban immunotherapy option alongside CIMAvax-EGF. While both target NSCLC, they work through different mechanisms — Vaxira targets the NeuGcGM3 ganglioside, while CIMAvax-EGF targets the EGF (Epidermal Growth Factor) pathway. In some cases, the Cuban oncology team may determine that one is more appropriate than the other based on the patient's specific cancer characteristics.
Vaxira is not FDA-approved and is not available in the United States. It is registered in Cuba and several other countries. American patients can access Vaxira treatment in Cuba through SMC Salud's international patient program.
How Vaxira Differs from U.S. Immunotherapy
American lung cancer patients may be familiar with U.S. immunotherapy drugs called checkpoint inhibitors — Keytruda (pembrolizumab), Opdivo (nivolumab), and Tecentriq (atezolizumab). Vaxira works through a fundamentally different mechanism:
U.S. Checkpoint Inhibitors (Keytruda, Opdivo, Tecentriq): • Mechanism: Release the 'brakes' on the immune system, allowing T-cells to attack cancer cells • Target: PD-1/PD-L1 or CTLA-4 immune checkpoint proteins • Administration: Intravenous infusion in a hospital/clinic setting • Indication: Used as first-line or second-line therapy, depending on PD-L1 expression • Side effects: Immune-related adverse events (colitis, pneumonitis, hepatitis, dermatitis) • Cost: $100,000-$150,000+ per year
Cuba's Vaxira (Racotumomab): • Mechanism: Active immunotherapy — induces the patient's immune system to produce antibodies against NeuGcGM3 ganglioside on tumor cells • Target: NeuGcGM3 ganglioside (tumor-specific antigen) • Administration: Subcutaneous injection (less invasive than IV infusion) • Indication: Maintenance therapy after first-line treatment for advanced NSCLC • Side effects: Generally mild (injection-site reactions, flu-like symptoms) • Cost: Significantly lower than U.S. checkpoint inhibitors
Key difference: Vaxira is an active immunotherapy (a vaccine that stimulates the patient's own immune response), while checkpoint inhibitors are passive immunotherapy (antibodies that block immune checkpoints). Vaxira is typically used as maintenance therapy after first-line treatment, while checkpoint inhibitors may be used earlier in the treatment sequence. The Cuban oncology team evaluates each patient to determine whether CIMAvax-EGF, Vaxira, or CIMAher is most appropriate for their specific cancer.
Eligibility & Treatment Process for Americans
Eligibility for Vaxira is determined through medical review of the patient's diagnosis, staging, prior treatments, and overall health:
Required documentation for U.S. patients: • Pathology reports confirming NSCLC diagnosis and subtype • Recent CT/MRI/PET imaging (within 3 months) • Tumor marker results • Summary of all prior treatments (chemotherapy regimens, radiation, surgery, immunotherapy) • Current medications and overall health status • PD-L1 expression results (if available)
The Cuban oncology team reviews these records to confirm: • Cancer type, subtype, and stage • That first-line therapy has been completed • Overall health and performance status • NeuGcGM3 pathway relevance to the patient's cancer • Absence of contraindications • Whether Vaxira, CIMAvax-EGF, or CIMAher is most appropriate
The treatment process follows the same structure as the CIMAvax-EGF program: arrival & evaluation (3-5 days), induction (2-4 weeks), and maintenance (ongoing). English-speaking coordinators manage all logistics, and the patient's accompanying family member is accommodated nearby. After the program, the Cuban medical team provides a comprehensive report for the patient's U.S. oncologist, and telemedicine follow-up consultations help coordinate ongoing care.
Frequently Asked Questions
Is Vaxira (racotumomab) FDA-approved?
No. Vaxira is not FDA-approved and is not available in the United States. It is registered in Cuba and several other countries. American patients can access Vaxira treatment in Cuba through SMC Salud's international patient program. The treatment is administered by experienced oncology teams at specialized clinical facilities in Havana.
How is Vaxira different from Keytruda or Opdivo?
Vaxira is an active immunotherapy (a vaccine that stimulates your immune system to produce antibodies against NeuGcGM3 ganglioside on tumor cells). Keytruda and Opdivo are checkpoint inhibitors that release the 'brakes' on the immune system. Vaxira is administered as a subcutaneous injection (less invasive than IV infusion) and is used as maintenance therapy after first-line treatment. The Cuban oncology team determines which therapy is most appropriate for each patient.
Can I receive Vaxira if I've already had Keytruda or Opdivo?
Your case will be reviewed by the Cuban oncology team to determine compatibility with prior treatments. Having received checkpoint inhibitors does not automatically disqualify you, but the medical team needs to evaluate your complete treatment history, response to prior therapies, and current health status. Each case is evaluated individually.
Learn more about Cuba's comprehensive Cuban Cancer Immunotherapy for American Patients
View the full treatment programContinue Reading
CIMAvax-EGF in Cuba for U.S. Cancer Patients: Complete Guide
Complete guide for American cancer patients seeking CIMAvax-EGF immunotherapy in Cuba — Roswell Park collaboration, travel authorization, cost, eligibility, and how it compares to US immunotherapy options.
Read more Cuban BiotechnologyCIMAher (Nimotuzumab) for U.S. Cancer Patients: Head & Neck Cancer Guide
Complete guide to CIMAher (nimotuzumab) Cuban monoclonal antibody therapy for American head & neck cancer patients — mechanism, eligibility, and comparison with U.S. treatments.
Read more Clinical EvidenceCIMAvax-EGF Clinical Evidence: Trial Data, Survival Outcomes, and the Roswell Park Study
Comprehensive review of CIMAvax-EGF clinical evidence — Cuban trial data, survival outcomes, the Roswell Park Phase I/II study, and what the evidence means for American lung cancer patients.
Read moreBegin Your Path to Healing
Submit your inquiry and our international patient coordination team will review your case and respond within 24–48 hours with a personalized treatment recommendation.
Medical Review
Our specialists evaluate your medical history and imaging
Treatment Proposal
Receive a detailed program with timeline and costs
Travel Coordination
Complete visa, accommodation, and logistics support